Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018219369) A DOSAGE UNIT WITH PPIS (PROTON PUMP INHIBITORS)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/219369 International Application No.: PCT/CZ2018/000025
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
A61K 9/50 (2006.01) ,A61K 31/4439 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
50
Microcapsules
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Applicants:
ZENTIVA, K.S. [CZ/CZ]; U Kabelovny 130 102 37 Praha 10, CZ
Inventors:
PUCHLA, Katarina; SK
SEBEK, Pavel; CZ
Agent:
JIROTKOVA, Ivana; Rott, Ruzicka & Guttmann Vinohradska 37 120 00 Praha 2, CZ
Priority Data:
PV 2017-31502.06.2017CZ
Title (EN) A DOSAGE UNIT WITH PPIS (PROTON PUMP INHIBITORS)
(FR) UNITÉ DE DOSAGE AVEC IPP (INHIBITEURS DE POMPE À PROTONS)
Abstract:
(EN) The present invention relates to a dosage unit with the active ingredient PPI in a quantity of 15 to 85% by weight. In this case, the active ingredient is processed with at least one pharmaceutically acceptable substance into the form of a pellet that is provided with insulating and acid resistant coating. The active ingredient is selected from the group comprising lansoprazole, pantoprazole, racemic omeprazole or one of its enantiomers.
(FR) La présente invention concerne une unité de dosage ayant l'ingrédient actif d’IPP en une quantité de 15 à 85 % en poids. Dans ce cas, l'ingrédient actif est traité avec au moins une substance pharmaceutiquement acceptable sous la forme d'une pastille qui est pourvue d'un enrobage isolant et résistant à l'acide. Le principe actif est choisi dans le groupe comprenant le lansoprazole, le pantoprazole, l'oméprazole racémique ou l'un de ses énantiomères.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)